Sulindac-d3

Sulindac-d3 is intended for use as an internal standard for the quantification of sulindac (Item No. 10004386) by GC- or LC-MS. Sulindac is a non-steroidal anti-inflammatory drug (NSAID), selective COX-2 inhibitor (IC50s = 0.79 and >1,000 µM for COX-2 and COX-1, respectively), and prodrug form of sulindac sulfide (Item No. 10004387).1,2,3,4 Sulindac is reduced by intestinal bacteria to form sulindac sulfide.1 It inhibits acetic acid-induced writhing in mice and reduces paw edema induced by carrageenan in rats when administered at a dose of 100 mg/kg.3 Sulindac (60 mg/kg) reduces tumor growth in MiaPaCa-2 and BxPC-3 mouse xenograft models.4 Formulations containing sulindac have been used in the treatment of pain associated with arthritis, ankylosing spondylitis, and gout.WARNING This product is not for human or veterinary use.

[1] DAMIAN MASEDA  Emanuela R. NSAID-Gut Microbiota Interactions.[J]. Frontiers in Pharmacology, 2020: 1153. DOI: 10.3389/fphar.2020.01153
[2] C J GROSSMAN. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitors.[J]. Inflammation Research, 1995, 44 6: 253-257. DOI: 10.1007/bf01782978
[3] MASHOOQ A BHAT. Novel sulindac derivatives: synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activity.[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020: 921-934. DOI: 10.1080/14756366.2020.1746783
[4] MICHELE T YIP-SCHNEIDER. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo.[J]. Molecular Cancer Therapeutics, 2007, 6 6: 1736-1744. DOI: 10.1158/1535-7163.mct-06-0794